Determination of Specificity and Sensitivity in Detecting Myocardial Infarction Using the EDE CARDIO BIO-MAP Machine (CARDIO BIO-MAP)
Determination of Specificity and Sensitivity in Detecting Myocardial Infarction Using the EDE CARDIO BIO-MAP Machine, the EDE CARDIO BIO-MAP Study
The goal of this observational study is to learn whether a non-invasive electromagnetic wave scanner (EDE CARDIO BIO-MAP) can help diagnose myocardial infarction (heart attack) in adults (18 years and older) who come to the emergency department with chest pain and suspected myocardial infarction. The main questions it aims to answer are:
- How sensitive and specific is the EDE scanner in diagnosing myocardial infarction (MI) compared with standard blood tests (e.g., cardiac troponin)?
- How sensitive and specific are the immediate blood measurements from a portable lab device compared with conventional hospital laboratory measurements? Researchers will compare the results of the EDE scanner and the portable lab with standard hospital blood test results and the final clinical diagnosis to see how accurately each detects MI.
Participants will:
- Have a research visit (30 minutes to 1 hour) during their emergency care, including a quick scan with the Exponential Deep Examination (EDE) device (attached to a phone or tablet) and a small research blood sample tested on a portable lab device
- Repeat the scan and blood sample 4 to 6 hours later, only if a second blood draw is already needed for their clinical care
- Answer questions about their medical and social history, and allow the study team to collect relevant results from their medical record Scanner results will not be shared with participants or used for their clinical care.
Visão geral do estudo
Status
Condições
Descrição detalhada
Myocardial infarction is a leading cause of death and disability worldwide. Current diagnosis relies on clinical assessment, electrocardiogram, and blood measurement of cardiac biomarkers such as troponin. Faster, non-invasive diagnostic tools could be especially valuable in the emergency setting, where timely intervention is critical.
The Exponential Deep Examination Cardio Bio-Map is a non-invasive device, classified as Class 1 under the European Conformity marking system, that analyzes passive electromagnetic signals (0.1 to 300 gigahertz) using artificial intelligence to measure cardiac biomarkers without a blood draw. Results are available within 50 milliseconds. The device does not collect or store patient data. It produces an immediate printed report, and all data processing occurs locally within Qatar. During the COVID-19 pandemic, the same technology detected the SARS-CoV-2 virus with a specificity of 95.62% and a sensitivity of 93.71% compared with polymerase chain reaction testing and antibody testing. This study will evaluate whether the device can screen for myocardial infarction through measurement of cardiac biomarkers, both in biological samples (in vitro, using a portable laboratory device) and directly in patients (in vivo, using the scanner).
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Charbel Abi Khalil, MD,PhD
- Número de telefone: +974 4492 8484
- E-mail: cha2022@qatar-med.cornell.edu
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Participants will be recruited at Hamad Medical Corporation
Descrição
Inclusion Criteria:
- Age ≥18 years.
- Adults presenting to the emergency room for acute chest pain.
- English or Arabic speakers.
Exclusion Criteria:
- Pregnancy (self-reported).
- Adults with cognitive disorders.
- Unconscious patients.
- Citizens from countries where the General Data Protection Regulation (GDPR) applies, due to regulatory constraints.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Sensitivity and specificity of the EDE CARDIO BIO-MAP scanner(in vivo) for detecting myocardial infarction
Prazo: Baseline
|
Sensitivity (true positives / [true positives + false negatives]) and specificity (true negatives / [true negatives + false positives]) of the scanner in emergency room patients with suspected myocardial infarction, compared with standard hospital laboratory results (cardiac troponin, creatine kinase-myocardial band, myoglobin, B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptide) and the final clinical diagnosis in the medical record. |
Baseline
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Sensitivity and specificity of the portable lab's immediate blood measurements (in vitro)
Prazo: Baseline
|
Sensitivity and specificity of the portable lab's immediate blood measurements for myocardial infarction, compared with conventional hospital laboratory measurements, using a confusion matrix. |
Baseline
|
|
Accuracy of the EDE scanner
Prazo: Baseline
|
Accuracy = (true positives + true negatives) / all results; |
Baseline
|
|
Misclassification rate of the EDE scanner
Prazo: Baseline
|
Misclassification rate = (false positives + false negatives) / all results; |
Baseline
|
|
Precision of the EDE scanner
Prazo: Baseline
|
precision = true positives / (true positives + false positives) |
Baseline
|
|
Accuracy of the portable lab
Prazo: Baseline
|
Accuracy = (true positives + true negatives) / all results; |
Baseline
|
|
Misclassification rate of the portable lab
Prazo: Baseline
|
Misclassification rate = (false positives + false negatives) / all results; |
Baseline
|
|
Precision of the portable lab
Prazo: Baseline
|
precision = true positives / (true positives + false positives) |
Baseline
|
|
Correlation Between EDE Scanner and Portable Laboratory Values for Cardiac Biomarkers
Prazo: Baseline
|
Pearson or Spearman correlation coefficient between scanner and portable lab values for cardiac biomarkers : Troponin T, Troponin I, Myoglobin, B-type Natriuretic Peptide, NT-proBNP, and Creatine Kinase-MB. |
Baseline
|
|
Predictive power of each cardiac biomarker for myocardial infarction
Prazo: Baseline
|
Logistic regression, area under the receiver operating characteristic curve, and optimal diagnostic cutoffs for each cardiac biomarker: Troponin T, Troponin I, Myoglobin, B-type Natriuretic Peptide, NT-proBNP, and Creatine Kinase-MB. |
Baseline
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in cardiac biomarker levels between initial assessment and 4-6 hour follow-up
Prazo: Baseline and 4-6 hours after initial assessment
|
Change in cardiac biomarker levels( Troponin T, Troponin I, Myoglobin, B-type Natriuretic Peptide, NT-proBNP, and Creatine Kinase-MB) between the initial assessment and the follow-up, in participants who have a second clinical blood draw. |
Baseline and 4-6 hours after initial assessment
|
|
Diagnostic performance of the scanner by sex
Prazo: Baseline
|
Subgroup analysis of scanner sensitivity and specificity by sex |
Baseline
|
|
Diagnostic performance of the scanner by age group
Prazo: Baseline
|
Subgroup analysis of scanner sensitivity and specificity by age group |
Baseline
|
|
Diagnostic performance of the scanner by symptom profile
Prazo: Baseline
|
Subgroup analysis of scanner sensitivity and specificity by symptom profile. |
Baseline
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Charbel Abi Khalil, MD,PhD, Weill Cornell Medicine-Qatar
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 23-00017
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
ongoing discussion with the sponsor
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .